市場調査レポート
商品コード
1462315
シナジスの市場規模、予測、市場考察(2032年)SYNAGIS Market Size, Forecast, and Market Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
シナジスの市場規模、予測、市場考察(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
シナジス(パリビズマブ)は、組換えDNA技術により産生されたヒト化モノクローナル抗体(IgG1к)で、RSVのFタンパク質のA抗原部位のエピトープを指向します。パリビズマブは、ヒト抗体(95%)とマウス抗体(5%)の複合抗体です。ヒト重鎖配列はヒトIgG1の定常ドメインとVH遺伝子CorとCessの可変フレームワーク領域に由来します。ヒト軽鎖配列は、Cкの定常ドメインとVL遺伝子K104の可変フレームワーク領域とJк-4に由来します。マウス配列は、マウスモノクローナル抗体Mab 1129から相補性決定領域をヒト抗体フレームワークに移植するプロセスで得られました。パリビズマブは2本の重鎖と軽鎖からなり、分子量は約148,000Daです。シナジスは、無菌の保存料なしの液剤として、1mLあたり100mgで筋肉内注射により投与されます。シナジスの生産には、チメロサールやその他の水銀含有塩は使用されません。溶液のpHは6.0であり、透明またはわずかに不透明です。シナジス液剤100mg単回投与バイアルは、1mL中、パリビズマブ100mgのほか、塩化物(0.5mg)、グリシン(0.1mg)、ヒスチジン(3.9mg)を含みます。シナジス液剤50mg単回投与バイアルは、パリビズマブ50mgを含み、0.5mLの容量で、塩化物(0.2mg)、グリシン(0.06mg)、ヒスチジン(1.9mg)を含みます。
当レポートでは、主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)における呼吸器合胞体ウイルス(RSV)向けシナジスについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。
"SYNAGIS Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about SYNAGIS for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the SYNAGIS for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the SYNAGIS for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SYNAGIS market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.
SYNAGIS (Palivizumab) is a humanized monoclonal antibody (IgG1к) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of Cк and the variable framework regions of the VL gene K104 with Jк-4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved grafting the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy and light chains and has a molecular weight of approximately 148,000 Da. SYNAGIS is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. Thimerosal or other mercury-containing salts are not used in the production of SYNAGIS. The solution has a pH of 6.0 and should appear clear or slightly opalescent. Each 100 mg single-dose vial of SYNAGIS liquid solution contains 100 mg of palivizumab and also contains chloride (0.5 mg), glycine (0.1 mg), and histidine (3.9 mg) in a volume of 1 mL. Each 50 mg single-dose vial of SYNAGIS liquid solution contains 50 mg of palivizumab and also contains chloride (0.2 mg), glycine (0.06 mg), and histidine (1.9 mg), in a volume of 0.5 ml.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SYNAGIS Analytical Perspective by DelveInsight
This report provides a detailed market assessment of SYNAGIS for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of SYNAGIS for RSV covering trial interventions, trial conditions, trial status, start and completion dates.